Agendia licenses two diagnostics to Ferrer

Netherlands-based Agendia BV has signed an agreement that will give Ferrer exclusive rights to sell two of its signature cancer diagnostic services. The products licensed to the Spanish firm are MammaPrint, a prognostic test that uses a 70-gene signature to indicate risk of breast cancer tumor recurrence, and CupPrint, a gene expression profiling service which offers a fast and reliable method of identifying the primary tumor site in cancer of unknown primary.

Under the exclusive distribution deal, Ferrer has gained rights to sell the tests in Germany, France, Italy and Portugal, in addition to a current agreement signed in 2007 covering Spain.

"We are confident that Ferrer inCode is the right partner for the successful expansion of MammaPrint and CupPrint into these additional European markets," said Bernhard Sixt, chief executive of Agendia. "This agreement will allow us to increase the availability of our services to more customers in these countries, with the result being that more patients and their physicians will have access to the valuable information provided by these tests," he added.